Haemoglobin A1c cut-off point to identify a high risk group of future diabetes: results from the Omiya MA Cohort Study

M. Kato, M. Noda, H. Suga, T. Nakamura, M. Matsumoto and Y. Kanazawa for the Omiya MA Cohort Study Group

Abstract

Aims Using the HbA1c level to define diabetes has several advantages and these advantages also apply to define a high-risk group. However, the risk of diabetes increases as HbA1c increases and a certain degree of arbitrariness in the cut-off for the high risk group is unavoidable. The aim of this study was to determine the HbA1c cut-off for defining a high-risk group that corresponds to the fasting plasma glucose cut-off by comparing the risk of diabetes against the fasting plasma glucose and HbA1c levels in the Japanese population.

Methods A retrospective cohort study was conducted using data from annual health examinations performed in Omiya city. A total of 11,271 subjects between the ages of 40 and 79 years without diabetes at baseline were followed for up to 7 years. According to the new diagnostic criteria, diabetes was defined as an fasting plasma glucose level ≥ 7 mmol/l or an HbA1c level ≥ 48 mmol/mol (≥ 6.5%) or a self-report. The HbA1c cut-off corresponding to the fasting plasma glucose cut-off was determined using the incidence, hazard ratio, and a receiver operating characteristic analysis.

Results Eight hundred and sixty subjects developed diabetes. The incidence, hazard ratio, and receiver operating characteristic analysis all indicated that an HbA1c cut-off of 39 mmol/mol (5.7%) corresponded to an fasting plasma glucose level of 5.6 mmol/l.

Conclusions Our results suggested that the HbA1c cut-off for high-risk of diabetes should be 39 mmol/mol (5.7%), consistent with the American Diabetes Association recommendation. Further research is needed to determine whether our results are applicable to other populations.

Keywords diabetes, epidemiology, fasting blood glucose, HbA1c, impaired fasting glucose

Introduction

Haemoglobin A1c is a marker of cumulative glycaemic exposure over the preceding 2- to 3-month period and has been used as a monitoring tool for glycaemic control in diabetic patients. In January 2010, the American Diabetes Association (ADA) released a new definition for diabetes mellitus using an HbA1c criterion (≥ 48 mmol/mol, ≥ 6.5%) in addition to the conventional fasting plasma glucose (FPG) criterion [1]. In July 2010, the Japan Diabetes Society also released a new definition of diabetes mellitus that included the HbA1c criterion [2]. Recently, the World Health Organization released an expert consultation report that accepted HbA1c as an additional test for the diagnosis of diabetes. [3].

Using the HbA1c level to define diabetes has several advantages over using the FPG level, such as the absence of the need to fast and a lower level of biological variability, and these advantages are also true for the definition of a high-risk group based on the HbA1c level. The American Diabetes Association
HbA1c levels in a Japanese population. Comparing the risk of developing diabetes against the FPG and HbA1c levels is unavoidable. The aim of this study was to determine an HbA1c cut-off value for defining a high-risk group that corresponds to the FPG cut-off value (5.6 mmol/l) [1,2] by comparing the risk of developing diabetes against the FPG and HbA1c levels in a Japanese population.

Participants and methods

This retrospective cohort study was conducted using anonymous data from annual health examinations performed in Omiya city by the Omiya Medical Association between 2000 (baseline) and 2007. The annual health examinations included a short questionnaire about medical condition and lifestyle. The questionnaire asked about the status (not present, under treatment, cured, or left untreated) of several medical conditions such as hypertension, cardiovascular disease, cancer, and diabetes.

Subjects who completed a health examination in 2000 were included in the present analysis if they were between the ages of 40 and 79 years and if their FPG and HbA1c data were available at baseline (in 2000) (n = 24 694: 8103 men, 16 591 women). Subjects with missing baseline data (n = 6) and subjects with heart disease, stroke, chronic liver disease, kidney disease or any type of cancer at baseline (n = 3413) were excluded from the analysis. Because the present study examined the incidence of diabetes, health examination participants with diabetes at baseline (n = 1933) were also excluded. Subjects who did not undergo an annual health examination in 2001 (n = 8076) were subsequently excluded from the analysis because of the lack of follow-up data. Compared with the subjects who underwent an annual health examination in 2001, the subjects who did not undergo an annual health examination in 2001 were somewhat younger (mean age 61.2 years vs. 58.4 years), but no significant differences in their baseline FPG level (mean FPG, 5.2 mmol/l vs. 5.2 mmol/l) or HbA1c level [mean HbA1c 34 mmol/mol (5.3%) vs. 34 mmol/mol (5.3%)] were observed. The remaining cohort consisted of 11 271 subjects (3279 men and 7992 women).

Subjects were regarded as incident cases of diabetes if they became diabetic [FPG ≥ 7 mmol/l, HbA1c ≥ 48 mmol/mol, (≥ 6.5%) or a response of ‘under treatment’, ‘cured’ or ‘left untreated’ to the question regarding diabetes status] for the first time during the course of the follow-up period. Subjects were regarded as censored cases if any of their annual health examination data was missing or their diabetes status was undetermined (missing FPG, HbA1c or questionnaire information) for the first time during the course of the follow-up period.

The HbA1c concentration was measured at a central laboratory using high-performance liquid chromatography [HLC-Tosoh Corporation, Tokyo, Japan] and calibrated using the standard calibrators of the Japan Diabetes Society. The Japan Diabetes Society value for HbA1c can be transformed to a National Glycohemoglobin Standardization Program (NGSP) equivalent value by adding 0.4 to the Japan Diabetes Society value [2]; all the HbA1c values in this manuscript were represented as the NGSP equivalent value. We used the HbA1c threshold for the diagnosis of diabetes [48 mmol/mol (6.5%)] according to the new diagnostic criteria for diabetes adopted by the American Diabetes Association [1] and the Japan Diabetes Society [2].

To examine the association between FPG (or HbA1c) and the risk of future diabetes, we calculated the incidence of diabetes according to the baseline FPG (or HbA1c) level. To evaluate the risk of diabetes according to the FPG (or HbA1c) level, we calculated the hazard ratios adjusted for sex, age (categorized as 40–49, 50–59, 60–69 and 70–79 years), body mass index (categorized as < 19, 19–20.9, 21–22.9, 23–24.9, 25–26.9, 27–28.9 and ≥ 29 kg/m²), history of hypertension, family history of diabetes, alcohol intake (never, ex-drinker, occasional drinker and habitual drinker) and smoking status (never, ex-smoker and current smoker). As the data regarding diabetes was obtained at 1-year intervals, we treated the data as grouped survival time and analysed it using a complementary log-log regression model which corresponds to a proportional hazard model in continuous time cases [4].

Results

The baseline characteristics of the subjects are shown in Table 1. At baseline, the proportion of subjects with an FPG level ≥ 5.6 mmol/l was 22.6% and the proportions of subjects with an HbA1c level ≥ 38 mmol/mol (≥ 5.6%) and ≥ 39 mmol/mol (≥ 5.7%) were 22.7% and 15.5%, respectively. During the 7-year follow-up period (average follow-up period, 3.8 years), 860 subjects (354 men and 506 women) were identified as incident cases of diabetes by annual health checkups. Among the 860 incident cases, 394 cases were diagnosed according to the FPG criterion (FPG ≥ 7 mmol/l) and 443 cases were diagnosed according to the HbA1c criterion [HbA1c level ≥ 48 mmol/mol (≥ 6.5%)]. Among these incident cases, 110 cases were diagnosed using both the FPG and HbA1c criteria. The remaining 133 (≈ 860 – 394 – 443 + 110) cases were diagnosed according to the self-report (answered ‘under treatment’, ‘cured’, or ‘left untreated’ to the question regarding diabetes status) only. The incidence of diabetes increased as the baseline FPG or HbA1c value increased and an almost similar pattern was observed irrespective of sex or age (see the Supporting Information, Fig. S1). The incidence according to the baseline FPG and HbA1c values are shown together in Fig. 1. In Fig. 1, the horizontal axes for FPG and HbA1c were placed so that the two curves for the incidence overlapped. The incidence (per 1000 person-years) for an FPG level of 5.6–5.8 mmol/l was 29.0 (95% CI, 24.3–34.5) and
those for a HbA1c level of 39 mmol/mol (5.7%) and 38 mmol/mol (5.6%) were 35.4 (95% CI 28.8–43.2) and 26.4 (95% CI 21.2–32.7), respectively. As shown in Fig. 1, an HbA1c value of around 39 mmol/mol (5.7%) [between 38 mmol/mol (5.6%) and 39 mmol/mol (5.7%)] corresponded to an FPG level of 5.6 mmol/l.

The hazard ratios according to the baseline FPG or HbA1c values adjusted for sex, age, body mass index, history of hypertension, family history of diabetes, alcohol drinking status and smoking status are shown in the Supporting Information (Tables S1 and S2, respectively), and the hazard ratios are also shown together in Fig. 2. An FPG or HbA1c level with an almost constant incidence (< 4.4 mmol/l for FPG and ≤ 5.2% [≤ 33 mmol/mol] for HbA1c) was selected as a reference (see Figure 1). In Fig. 2, the horizontal axes for FPG and HbA1c were placed so that the two curves for the hazard ratios overlapped. The hazard ratio for an FPG level of 5.6 mmol/l was 7.08 (95% CI 3.11–16.1) and that for an HbA1c level of 5.7% (39 mmol/mol) was 6.53 (95% CI 4.87–8.75). As shown in Fig. 2, an HbA1c value of around 5.7% (39 mmol/mol) also

### Table 1 Baseline characteristics of subjects

|                      | Total (n = 11 271) | Men (n = 3279) | Women (n = 7992) |
|----------------------|---------------------|----------------|------------------|
| Age (years)          | 62 (55–68)          | 65 (60–70)     | 61 (54–67)       |
| BMI (kg/m²)          | 22.8 (2.9)          | 23.3 (2.7)     | 22.6 (3.0)       |
| Fasting plasma glucose (mmol/l) | 5.1 (4.8–5.5)   | 5.3 (4.9–5.6)  | 5.1 (4.8–5.4)    |
| HbA1c (%)            | 5.3 (5.1–5.5)       | 5.3 (5.1–5.5)  | 5.3 (5.1–5.5)    |
| HbA1c (mmol/mol)     | 34 (32–37)          | 34 (32–37)     | 34 (32–37)       |
| History of hypertension (yes) | 71.4                | 66.3           | 73.5             |
| Alcohol              |                     |                |                  |
| Never                | 52.6                | 20.1           | 65.9             |
| Ex-drinker           | 1.0                 | 2.2            | 0.6              |
| Occasional-drinker   | 26.9                | 28.1           | 26.4             |
| Habitual drinker     | 19.3                | 49.6           | 7.1              |
| Smoking              |                     |                |                  |
| Never                | 76.5                | 42.4           | 90.6             |
| Ex-smoker            | 9.0                 | 25.2           | 2.3              |
| Current smoker       | 14.5                | 32.5           | 7.1              |

Age, fasting plasma glucose and HbA1c are represented as the median (interquartile range), BMI is represented as the mean (standard deviation); the other characteristics are represented as proportions.
corresponded to an FPG level of 5.6 mmol/l in terms of the hazard ratios. The receiver operating characteristic curves for FPG and HbA1c are shown in Fig. 3. The curves for FPG and HbA1c are almost similar, indicating that FPG and HbA1c have almost the same ability to detect future diabetes. The area under the curve values for FPG and HbA1c were 0.82 (95% CI 0.80–0.83) and 0.82 (95% CI 0.80–0.84), respectively. The optimal cut-off values, which maximize the sum of the sensitivity plus specificity, were 5.5 mmol/l (sensitivity of 68% and specificity of 81%) and 5.6% (5.6 mmol/mol) (sensitivity of 70% and specificity of 81%), respectively. An FPG level of 5.6 mmol/l (sensitivity of 64% and specificity of 83%) and an HbA1c level of 39 mmol/mol (5.7%) (sensitivity of 61% and specificity of 89%) were both adjacent to the optimal cut-offs and had a similar position on the receiver operating characteristic curves. In the receiver operating characteristic analysis, an FPG level of 5.6 mmol/l once again corresponded to an HbA1c level of around 39 mmol/mol (5.7%) [between 38 mmol/mol (5.6%) and 39 mmol/mol (5.7%)]. The correspondence between an FPG level of 5.6 mmol/l and an HbA1c level of 39 mmol/mol (5.7%) held true for both men and women.

**Discussion**

For both the FPG and the HbA1c levels, the risk of diabetes increased as the FPG or HbA1c level increased, and no clear cut-off point exists above which the risk of diabetes increases markedly. Therefore, a certain degree of arbitrariness in the cut-off point for the high-risk group is unavoidable. In the case of the FPG level, the American Diabetes Association defined the cut-off point for the group with a high risk of developing diabetes (impaired fasting glucose) as 5.6 mmol/l [1,5], and this cut-off can also be applied to the Japanese population [6–8]. Thus, it seems reasonable to determine the HbA1c cut-off point for the high-risk group in a manner such that the risk of the
group defined by the cut-off point is similar to that of the high-risk group determined using the FPG cut-off. Our data for the incidence, hazard ratio and receiver operating characteristic analysis showed that an HbA1c cut-off value of 39 mmol/mol (5.7%) corresponds to the FPG cut-off value of 5.6 mmol/L. When prevalence was considered, an FPG level of 5.6 mmol/L corresponded to an HbA1c level of about 38 mmol/mol (5.6%) [between 38 mmol/mol (5.6%) and 39 mmol/mol (5.7%)], and the prevalence of individuals in the high-risk group defined by an HbA1c level of 5.7% was smaller than that defined by the FPG level. Several cross-sectional studies have examined the correlation between FPG and HbA1c and have found that an HbA1c level around 5.6–5.7% appeared to be equivalent to an FPG level of 5.6 mmol/l [9,10]. In the present study, we also analysed the correlation between FPG and HbA1c, and an FPG level of 5.6 mmol/l and 5.8 mmol/l corresponded to an HbA1c level of 38 mmol/mol (5.6%) and 39 mmol/mol (5.7%), respectively (data not shown). Taking into account that the FPG cut-off value of 5.6 mmol/l (100 mg/dl) must be a round number, we think that these results also support our conclusion.

Several papers have discussed the relationship between HbA1c and the risk of developing diabetes [11–13], and some of these papers have been from Japan [14–16]. Based on these reports, the American Diabetes Association defined subjects with an HbA1c level of between 39 mmol/mol (5.7%) and 46 mmol/mol (6.4%) as ‘categories of increased risk for diabetes’ [1]. Similarly, the Japan Diabetes Society defined subjects with an HbA1c level of between 42 mmol/mol (6.0%) and 46 mmol/mol (6.4%) as ‘suspected diabetes mellitus cannot be excluded’ and between 38 mmol/mol (5.6%) and 39 mmol/mol (5.9%) as ‘a group with a high risk for developing diabetes mellitus in the future’ [2]. However, the analyses in the above-mentioned studies were based on categorized HbA1c values and the proposed cut-off value was determined with some arbitrariness, as no clear cut-off point exists above which the risk of diabetes increases markedly. In this paper, the HbA1c cut-off value was determined by comparing the risk of diabetes with the FPG cut-off level; to our knowledge, this is the first attempt to determine the cut-off value in this manner. We believe that this is a logical and reasonable way to define the cut-off value for HbA1c and that it provides a solid basis for the overall definition of the cut-off value of 39 mmol/mol (5.7%).

This study had several strengths. First, diabetes was defined using both FPG and HbA1c according to the recent American Diabetes Association [1] and Japan Diabetes Society [2] diagnostic criteria for diabetes mellitus. Diagnosing diabetes based on the HbA1c values is quite appealing, especially for epidemiological studies, because no glucose tolerance test or fasting blood sample is required. In addition, chronic hyperglycaemia, which is characteristic of diabetes mellitus, can be detected using a single measurement using HbA1c. Moreover, because the variability of HbA1c is lower than that of FPG or the 2-h plasma glucose values [17–19], the potential risk for misclassification is also expected to be low. Second, the relatively large numbers of subjects and the long follow-up period of the present study make it possible to analyse the incidence using a relatively small HbA1c interval. This is an important point because the correct identification of a high-risk group is only possible if a precise cut-off value is used. The present study also had several limitations. First, ‘diabetes’ in the present study was defined using a single measurement of FPG and of HbA1c. Defining diabetes using a single measurement of FPG may lead to an overestimation of the incidence of diabetes, as subjects with transient hyperglycaemia may be regarded as incident cases of diabetes. Although uncommon, subjects with a spuriously high HbA1c level may also be incorrectly regarded as having diabetes. To investigate this point, we analysed the data by defining diabetes as an FPG ≥ 7 mmol/l and (not ‘or’) an HbA1c ≥ 48 mmol/mol (≥ 6.5%) in addition to the self-report. In this analysis, 515 of the 11 486 subjects developed diabetes, and although the incidence decreased, the correspondence between an FPG of 5.6 mmol/l and an HbA1c of 39 mmol/mol (5.7%) did not change. Second, although the diagnosis of diabetes based on the HbA1c values has many advantages, several problems also exist. In addition to from the standardization problem, HbA1c values do not reflect the plasma glucose level for subjects with abnormal haemoglobin or diseases that affect erythrocyte turnover, such as anaemia or liver cirrhosis [19–21]. However, these problems did not seem to be serious in the present study because (1) we excluded subjects with severe diseases, such as liver cirrhosis, and (2) diabetes was diagnosed based not only on the HbA1c value, but also using the FPG level as well as self-report. Third, a relatively large number of subjects (about 42%) did not undergo an annual health check-up in 2001. This limitation arose from the study design, as the participants were allowed to decide whether they wished to undergo a health examination. Although the subjects who did not undergo an annual health examination in 2001 were younger than the subjects who underwent an annual health examination in 2001, no significant differences in the baseline FPG and HbA1c levels were observed; consequently, a large bias was not thought to exist. Fourth, the subjects of the present study were participants of health check-ups and may not represent the general population. Generally, the participants of health check-ups are more health conscious than those who do not participate. However, whether the risk of diabetes, as determined using the FPG or HbA1c levels exists between health check-up participants and non-participants remain unclear, and further research is needed to clarify this point.

Our study is one of several studies to reveal an association between HbA1c and the future risk of diabetes in the Japanese population, and to determine the HbA1c cut-off value for a high-risk group for future diabetes in not only a logical and reasonable but also a natural way, that is, by determining the HbA1c cut-off value based on its correspondence with the FPG cut-off value according to the risk of developing diabetes.

Competing interests

Nothing to declare.
Acknowledgements
The authors are grateful to Haruhito Masuda (Omiya Medical Association) for his assistance. This study was supported by a Community Medicine Research Grant from Saitama city and a grant from the Japan Diabetes Foundation. Members of the Omiya MA Cohort Study Group, Omiya Medical Association are: H. Sugah (Chair); M. Matsumoto; C. Satomura, MD; T. Nakamura; K. Nakayama, MD; R. Kawaguchi, MD, PhD; M. Mitani, MD; and outside members M. Noda, M. Kato and Y. Kanazawa.

References
1 American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2010; 33: S62–S69.
2 The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 2010; 1: 212–228.
3 World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Available at http://www.who.int/entity/diabetes/publications/report-hba1c_2011.pdf last accessed 24 February 2011.
4 Prentice RL, Gloeckler LA. Regression analysis of grouped survival data with application to breast cancer data. Biometrics 1978; 34: 57–67.
5 Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al. The Committee of the Japan Diabetes Society on the Diagnostic Criteria for Diabetes Mellitus and Glucose Metabolism Disorder – a new category of fasting plasma glucose values: ‘high-normal’. J Japan Diab Soc 2008; 51: 281–283.
6 Kato M, Noda M, Sugah, Matsumoto M, Kanazawa Y. Fasting plasma glucose and incidence of diabetes – implication for the threshold for impaired fasting glucose: results from the population-based Omiya MA Cohort Study. J Atheroscler Thromb 2009; 16: 857–861.
7 Noda M, Kato M, Takahashi Y, Matushita Y, Mizoue T, Inoue M et al. Fastening plasma glucose and 5-year incidence of diabetes in the JPHC diabetes study – suggestion for the threshold for impaired fasting glucose among Japanese. Endocr J 2010; 57: 629–637.
8 Ito C, Maeda R, Ishida S, Sasaki H, Harada H. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Res Clin Pract 2000; 50: 223–230.
9 Mohan V, Vijayachandirka V, Gokulakrishnan K, Anjana RM, Ganesan A, Weber MB et al. A1C cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care 2010; 33: 515–519.
10 Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, Ballard KM et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care 2010; 33: 1665–1673.
11 Cederberg H, Saukonen T, Laakso M, Jokelainen J, Harkonen P, Timonen M et al. Postchallenge glucose, A1C, and fasting glucose as predictors of type 2 diabetes and cardiovascular disease: a 10-year prospective cohort study. Diabetes Care 2010; 33: 2077–2083.
12 Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Hassinen SM. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 2010; 33: 2104–2109.
13 Shimazaki T, Kadowaki T, Ohyama Y, Ohe K, Kubota K. Hemoglobin A1c (HbA1c) predicts future drug treatment for diabetes mellitus: a follow-up study using routine clinical data in a Japanese university hospital. Transl Res 2007; 149: 196–204.
14 Inoue K, Matsumoto M, Kobayashi Y. The combination of fasting plasma glucose and glycosylated hemoglobin predicts type 2 diabetes in Japanese workers. Diabetes Res Clin Pract 2007; 77: 451–458.
15 Sato KK, Hayashi T, Harita N, Yoneda T, Nakamura Y, Endo G et al. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care 2009; 32: 644–646.
16 Moo JY, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996; 39: 298–305.
17 Rohlfing C, Wiedmayer HM, Little R, Grotz VI, Tennill A, England J et al. Biological variation of glycohemoglobin. Clin Chem 2002; 48: 1116–1118.
18 Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48: 436–472.
19 Schnell WJ, Liehminger A, Roller RE, Lipp RW, Kreis GJ. Hemoglobin variants and determination of glycated hemoglobin (HbA1c). Diabetes Metab Res Rev 2001; 17: 94–98.
20 Lahousen T, Hegenbarth K, Ille R, Lipp RW, Krause R, Little RR et al. Determination of glycated hemoglobin in patients with advanced liver disease. World J Gastroenterol 2004; 10: 2284–2286.

Supporting Information
Additional Supporting Information may be found in the online version of this article.

Figure S1. Incidence rate of diabetes mellitus according to baseline fasting plasma glucose (FPG) and HbA1c levels.

FPG was divided into intervals with the same width (0.28 mmol/L [5 mg/dL]).

Table S1. Hazard ratios for the incidence of diabetes mellitus according to the baseline fasting plasma glucose (FPG) levels.

Table S2. Hazard ratios for the incidence of diabetes mellitus according to the baseline HbA1c levels.

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.